Bearberry in the Treatment of Cystitis (BRUMI)
Primary Purpose
Cystitis
Status
Not yet recruiting
Phase
Not Applicable
Locations
Hungary
Study Type
Interventional
Intervention
Fosfomycin
Bearberry
Sponsored by
About this trial
This is an interventional treatment trial for Cystitis focused on measuring bearberry, cystitis, uncomplicated cystitis, fosfomycin
Eligibility Criteria
Inclusion Criteria:
- premenopausal adult women
- diagnosis of acute uncomplicated cystitis (with the symptoms of dysuria, increased frequency, and urgency of urination and lower abdominal pain (suprapubic pain), that is presumed to be confined to the bladder; with no signs or symptoms that suggest an upper tract or systemic infection)
- a sum-score of of ≥6 for the typical uncomplicated urinary tract infections symptoms (frequency, urgency, painful urination, incomplete emptying, suprapubic pain, and visible hematuria) reported on the Acute Cystitis Symptom Score (ACSS) typical domain and pyuria (10 white blood cells/mm3 in a mid-stream specimen) at day 0
Exclusion Criteria:
- any renal disease
- upper urinary tract infection
- malformations of the urinary tract
- congenital disorders of the urinary tract
- catheter use
- pregnancy
- breastfeeding
- self-medication with bearberry or antibiotic use in the last 3 months
- 5 or more bearberry treatments in the previous year
- concomitant use of other antibiotics and NSAIDs
- contraindication for study drugs
- active malignancy
- immunodeficiency, including immunosuppressive treatment.
Sites / Locations
- Institute for Translational Medicine, University of Pécs
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Fosfomycin
Bearberry
Arm Description
a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A)
a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
Outcomes
Primary Outcome Measures
Change of symptom severity
the change of symptom severity of uncomplicated cystitis after 7 days of treatment. The improvement of symptoms will be determined by using the validated Hungarian version of the Acute Cystitis Symptom Score on day 0 and day 7 according to predefined thresholds
Secondary Outcome Measures
Number of patients without significant urine pathogens
number of patients with urine with <103 colony forming units (CFU)/ml on day 7
Number of urine pathogens
average number of CFU of pathogens (7 days after the start of the therapy) in urine
Frequency and severity of side effects
frequency and severity of side effects used a questionnaire
Recurrence of urinary tract infection (UTI)
follow-up after 90 days; severity and diagnostics of recurrences to be assessed by using the ACSS
Concurrent use of other medications
concurrent use of other over-the-counter (OTC) medications and food supplements that are started taking during the 7 day treatment trial.
Full Information
NCT ID
NCT05055544
First Posted
September 11, 2021
Last Updated
September 21, 2021
Sponsor
University of Pecs
1. Study Identification
Unique Protocol Identification Number
NCT05055544
Brief Title
Bearberry in the Treatment of Cystitis
Acronym
BRUMI
Official Title
BeaRberry in the Treatment of Acute UncoMplIcated Cystitis (BRUMI)- Protocol of a Multicentre, Randomized Double-Blind Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 2021 (Anticipated)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pecs
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this study is to assess the efficacy of bearberry in uncomplicated cystitis. Uncomplicated cystitis is a disease related to the infection of the urinary bladder. Typical symptoms are dysuria, urinary urgency, and frequent voiding of small volumes. Urinary tract infections are frequent in women, usually treated with antibiotics, since the disease is usually caused by bacteria.
Fosfomycin is a frequently used antibiotic for the treatment of uncomplicated cystitis. This medicine is typically prescribed by MDs. However, since uncomplicated cystitis is quite frequent, not all patients visit the doctor when experiencing the symptoms of this disease. The use of over-the-counter products (medicines and food supplements) to alleviate the symptoms is common. One of the most frequently used medicinal plants for this purpose is bearberry. Bearberry is a medicinal plant traditionally used for the treatment of cystitis. Its use is accepted by the European Medicine Agency as traditional herbal medicinal product for relief of symptoms of mild recurrent lower urinary tract infections such as burning sensation during urination and/or frequent urination in women. Although the experience gained during the traditional use and the laboratory experiments support the supposed beneficial effect of bearberry, its clinical efficacy has not been confirmed in well-designed clinical trials in comparison with standard antibiotic therapy. In this study, the efficacy of bearberry will be assessed in comparison with fosfomycin.
Premenopausal women experiencing the symptoms of uncomplicated cystitis will be randomly divided into two groups. Since it will be a double-blind trial, neither the participants nor the experimenters will know who is receiving a particular treatment. In group A, patients will receive a single dose of fosfomycin powder dissolved in water and 2 placebo tablets three times a day for 7 days. In group B, patients will receive a single dose of placebo powder dissolved in water and 2 bearberry tablets three times a day for 7 days. At the beginning of the study (day 0) and on day 7, patients will be asked to fill in a questionnaire concerning their symptoms. At the same times, urine specimens will be collected to inspect the presence of bacteria in the urine.
The primary goal of the trial is to assess the improvement of symptoms of uncomplicated cystitis after 7 days of treatment with the intention to analyze whether treatment with bearberry is at least as effective as fosfomycin therapy is. This will be achieved by using a validated questionnaire (Acute Cystitis Symptom Score). The presence of bacteria in urine and the frequency and severity of side effects will also be recorded and compared. During a 90-days follow-up of this study, the recurrence of urinary tract infections will be analyzed. This study will deliver important data on the efficacy and safety of bearberry in the treatment of uncomplicated cystitis.
Detailed Description
This randomized, controlled double-blind multicentre trial will assess the non-inferiority of bearberry (Arctostaphylos uva-ursi) in comparison with fosfomycin in the therapy of uncomplicated cystitis.
In clinical practice, acute uncomplicated cystitis is usually treated based on the clinical signs and symptoms. According to current guidelines, first-line drugs are fosfomycin trometamol, nitrofurantoin, nitroxoline, trimethoprim-sulfamethoxazole, and pivmecillinam. The advantage of fosfomycin is that a single is considered to be sufficient for the treatment of uncomplicated cystitis, resulting in better patient compliance compared to other antibiotics.
Bacterial resistance is one of the major drawback of antibiotic use. Therefore, the assessment of other medicines than currently used antibiotics is of primary importance. One of the most widely used over-the-counter medications in the treatment of urinary tract infection-related symptoms is bearberry. Although this plant has been used in traditional medicine for the treatment of acute cystitis, and the European Medicines Agency acknowledged its use as traditional herbal medicinal product used for the treatment of symptoms of mild recurrent lower urinary tract infections such as burning sensation during urination and/or frequent urination in women, the efficacy has not been assessed in well-designed clinical trials. Since several patients are using bearberry-based medicines, it is important to obtain clinical data on the efficacy and safety of this plant. The aim of this study is to assess the non-inferiority of bearberry in comparison with a standard antibiotic (fosfomycin) used in acute uncomplicated cystitis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystitis
Keywords
bearberry, cystitis, uncomplicated cystitis, fosfomycin
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a randomized, controlled, double-blinded, two-armed multicentre trial.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
504 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fosfomycin
Arm Type
Active Comparator
Arm Description
a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A)
Arm Title
Bearberry
Arm Type
Active Comparator
Arm Description
a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
Intervention Type
Drug
Intervention Name(s)
Fosfomycin
Intervention Description
a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
Intervention Type
Drug
Intervention Name(s)
Bearberry
Intervention Description
a single dose of placebo powder dissolved in 75 ml water and 2 bearberry tablets t.i.d. for 7 days (group B).
Primary Outcome Measure Information:
Title
Change of symptom severity
Description
the change of symptom severity of uncomplicated cystitis after 7 days of treatment. The improvement of symptoms will be determined by using the validated Hungarian version of the Acute Cystitis Symptom Score on day 0 and day 7 according to predefined thresholds
Time Frame
The 2 time points at which the measurement is assessed is the time of enrollment, after 7 days of treatment.
Secondary Outcome Measure Information:
Title
Number of patients without significant urine pathogens
Description
number of patients with urine with <103 colony forming units (CFU)/ml on day 7
Time Frame
The time point at which the measurement is assessed on day 7.
Title
Number of urine pathogens
Description
average number of CFU of pathogens (7 days after the start of the therapy) in urine
Time Frame
The time point at which the measurement is assessed on day 7.
Title
Frequency and severity of side effects
Description
frequency and severity of side effects used a questionnaire
Time Frame
The time point at which the measurement is assessed on day 7.
Title
Recurrence of urinary tract infection (UTI)
Description
follow-up after 90 days; severity and diagnostics of recurrences to be assessed by using the ACSS
Time Frame
The time point at which the measurement is assessed on day 90.
Title
Concurrent use of other medications
Description
concurrent use of other over-the-counter (OTC) medications and food supplements that are started taking during the 7 day treatment trial.
Time Frame
The time point at which the measurement is assessed on day 7.
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
premenopausal adult women
diagnosis of acute uncomplicated cystitis (with the symptoms of dysuria, increased frequency, and urgency of urination and lower abdominal pain (suprapubic pain), that is presumed to be confined to the bladder; with no signs or symptoms that suggest an upper tract or systemic infection)
a sum-score of of ≥6 for the typical uncomplicated urinary tract infections symptoms (frequency, urgency, painful urination, incomplete emptying, suprapubic pain, and visible hematuria) reported on the Acute Cystitis Symptom Score (ACSS) typical domain and pyuria (10 white blood cells/mm3 in a mid-stream specimen) at day 0
Exclusion Criteria:
any renal disease
upper urinary tract infection
malformations of the urinary tract
congenital disorders of the urinary tract
catheter use
pregnancy
breastfeeding
self-medication with bearberry or antibiotic use in the last 3 months
5 or more bearberry treatments in the previous year
concomitant use of other antibiotics and NSAIDs
contraindication for study drugs
active malignancy
immunodeficiency, including immunosuppressive treatment.
Facility Information:
Facility Name
Institute for Translational Medicine, University of Pécs
City
Pécs
ZIP/Postal Code
7624
Country
Hungary
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing URL
http://tm-centre.org/
Citations:
PubMed Identifier
18511178
Citation
Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008 Nov;54(5):1164-75. doi: 10.1016/j.eururo.2008.05.010. Epub 2008 May 21.
Results Reference
background
PubMed Identifier
21292654
Citation
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20. doi: 10.1093/cid/ciq257.
Results Reference
background
PubMed Identifier
24202878
Citation
Keating GM. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs. 2013 Nov;73(17):1951-66. doi: 10.1007/s40265-013-0143-y.
Results Reference
background
PubMed Identifier
20539810
Citation
Schmiemann G, Kniehl E, Gebhardt K, Matejczyk MM, Hummers-Pradier E. The diagnosis of urinary tract infection: a systematic review. Dtsch Arztebl Int. 2010 May;107(21):361-7. doi: 10.3238/arztebl.2010.0361. Epub 2010 May 28.
Results Reference
background
PubMed Identifier
29539622
Citation
Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner FM. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int. 2018;100(3):271-278. doi: 10.1159/000487645. Epub 2018 Mar 14.
Results Reference
background
PubMed Identifier
30765904
Citation
Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY. Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. Aust Prescr. 2019 Feb;42(1):14-19. doi: 10.18773/austprescr.2019.002. Epub 2019 Feb 1.
Results Reference
background
PubMed Identifier
26960938
Citation
Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016 Apr;29(2):321-47. doi: 10.1128/CMR.00068-15.
Results Reference
background
PubMed Identifier
8298585
Citation
Van Pienbroek E, Hermans J, Kaptein AA, Mulder JD. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. Pharm World Sci. 1993 Dec 17;15(6):257-62. doi: 10.1007/BF01871127.
Results Reference
background
PubMed Identifier
10890258
Citation
Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther. 1999 Nov;21(11):1864-72. doi: 10.1016/S0149-2918(00)86734-X.
Results Reference
background
PubMed Identifier
9624542
Citation
Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents. 1998 Apr;10(1):39-47. doi: 10.1016/s0924-8579(98)00021-1.
Results Reference
background
PubMed Identifier
29710295
Citation
Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627.
Results Reference
background
PubMed Identifier
32061811
Citation
Loras C, Mendes AC, Peixe L, Novais A, Alos JI. Escherichia coli resistant to fosfomycin from urinary tract infections: Detection of the fosA3 gene in Spain. J Glob Antimicrob Resist. 2020 Jun;21:414-416. doi: 10.1016/j.jgar.2020.01.023. Epub 2020 Feb 12.
Results Reference
background
PubMed Identifier
20851815
Citation
Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernandez S, Lazaro E, de Abajo FJ, Campos J; Spanish ESBL-EARS-Net Study Group. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010 Nov;65(11):2459-63. doi: 10.1093/jac/dkq346. Epub 2010 Sep 16.
Results Reference
background
PubMed Identifier
3724205
Citation
Moskalenko SA. Preliminary screening of far-eastern ethnomedicinal plants for antibacterial activity. J Ethnopharmacol. 1986 Mar;15(3):231-59. doi: 10.1016/0378-8741(86)90163-7.
Results Reference
background
PubMed Identifier
23295957
Citation
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
Results Reference
background
PubMed Identifier
6669604
Citation
Jahodar L, Leifertova I, Lisa M. Elimination of arbutin from the organism. Pharmazie. 1983 Nov;38(11):780-1. No abstract available.
Results Reference
background
PubMed Identifier
6495348
Citation
Divincenzo GD, Hamilton ML, Reynolds RC, Ziegler DA. Metabolic fate and disposition of [14C]hydroquinone given orally to Sprague-Dawley rats. Toxicology. 1984 Oct;33(1):9-18. doi: 10.1016/0300-483x(84)90012-x.
Results Reference
background
PubMed Identifier
11587357
Citation
Glockl I, Blaschke G, Vei M. Validated methods for direct determination of hydroquinone glucuronide and sulfate in human urine after oral intake of bearberry leaf extract by capillary zone electrophoresis. J Chromatogr B Biomed Sci Appl. 2001 Sep 25;761(2):261-6. doi: 10.1016/s0378-4347(01)00322-x.
Results Reference
background
PubMed Identifier
24457349
Citation
Alidjanov JF, Abdufattaev UA, Makhsudov SA, Pilatz A, Akilov FA, Naber KG, Wagenlehner FM. New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int. 2014;92(2):230-6. doi: 10.1159/000356177. Epub 2014 Jan 23. Erratum In: Urol Int. 2016;96(3):369.
Results Reference
background
PubMed Identifier
29732220
Citation
Magyar A, Alidjanov J, Pilatz A, Nagy K, Arthanareeswaran VKA, Poth S, Becsi A, Wagenlehner FME, Naber KG, Tenke P, Koves B. The role of the Acute Cystitis Symptom Score questionnaire for research and antimicrobial stewardship. Validation of the Hungarian version. Cent European J Urol. 2018;71(1):134-141. doi: 10.5173/ceju.2018.1530. Epub 2017 Jan 22.
Results Reference
background
PubMed Identifier
35750460
Citation
Toth B, Javorhazy A, Nyirady P, Csupor-Loffler B, Birinyi P, Zhanel G, Naber K, Langer R, Vorhendi N, Gede N, Vancsa S, Hegyi P, Csupor D. Bearberry in the treatment of acute uncomplicated cystitis (BRUMI): protocol of a multicentre, randomised double-blind clinical trial. BMJ Open. 2022 Jun 24;12(6):e057982. doi: 10.1136/bmjopen-2021-057982.
Results Reference
derived
Links:
URL
http://tm-centre.org/
Description
Related Info
Learn more about this trial
Bearberry in the Treatment of Cystitis
We'll reach out to this number within 24 hrs